文献速递浆细胞疾病造血干细胞移植与细胞治疗

我们到了吗?CAR-T细胞疗法在多发性骨髓瘤中的应用

Are we there yet? CAR-T therapy in multiple myeloma.
PubMed 文献 · Br J Haematol · 2024-11-19

本文综述了多发性骨髓瘤(MM)细胞免疫治疗的最新进展,重点为靶向B细胞成熟抗原(BCMA)的CAR-T疗法。BCMA CAR-T于2021年获美国FDA和欧洲EMA批准,但英国NICE批准仍在等待中。文章评估了新一代CAR、异体通用型CAR及靶向GPRC5D、FcRH5、CD19、SLAMF7等新抗原的临床与临床前数据,并探讨了克服耐药策略。

要点

  • 靶向BCMA的自体CAR-T已获FDA和EMA批准用于多发性骨髓瘤,NICE批准仍在等待中。
  • 经重度预处理MM患者的初始缓解率令人印象深刻,但患者仍会复发。
  • CAR-T制备昂贵耗时,且既往MM治疗损害T细胞适应性。

核心结论

  • 靶向BCMA的CAR-T疗法在重度预处理MM中初始缓解率令人印象深刻,但患者仍会复发。
  • CAR-T制备昂贵耗时,且既往MM治疗损害T细胞适应性。
  • 多种改进策略正在研究中,包括新一代CAR、异体通用型CAR及靶向其他MM抗原。

研究设计与样本

  • 本文为综述,评估了关于新型细胞免疫疗法的最新临床和临床前数据,并探讨克服耐药通路的策略。

主要发现

  • 靶向BCMA的自体CAR-T于2021年首次获美国FDA和欧洲EMA批准,NICE批准仍在等待中。
  • 经重度预处理MM患者的初始缓解率令人印象深刻,但患者仍会复发。
  • CAR-T制备昂贵耗时,且T细胞适应性受既往MM治疗损害。
  • 正在研究的策略包括新一代CAR、异体通用型CAR及靶向GPRC5D、FcRH5、CD19、SLAMF7等抗原。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The last few years have seen a revolution in cellular immunotherapies for multiple myeloma (MM) with novel antigen targets. The principle new target is B-cell maturation antigen (BCMA). Autologous chimeric antigen receptor T-cell (CAR-T) therapy directed against BCMA was first approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2021, although approval by the National Institute for Health and Care Excellent (NICE) is awaited. Initial response rates in patients with heavily pretreated MM have been impressive, but patients are still relapsing. Furthermore, CAR-T manufacturing is expensive and time-consuming, and T-cell fitness is impaired by prior MM treatment. Numerous strategies to improve outcomes and delivery of cellular immunotherapy are under investigation, including next-generation CARs, allogeneic 'off-the-shelf' CARs and targeting of other MM antigens including G protein-coupled receptor, class C, group 5, member D (GPRC5D), Fc receptor homologue 5 (FcRH5), cluster of differentiation (CD)19, signalling lymphocyte activation molecule family member 7 (SLAMF7) and several others. In this exciting and rapidly evolving treatment landscape, this review evaluates the most recent clinical and preclinical data pertaining to these new cellular immunotherapies and explores strategies to overcome resistance pathways. On the protracted journey to a long-term cure, we outline the challenges that lie ahead and ask, 'Are we there yet?'

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mirvis E, Benjamin R. Are we there yet? CAR-T therapy in multiple myeloma. Br J Haematol. 2024. PMID: 39558776. doi:10.1111/bjh.19896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。